SPARC Share Price Surges Up to 11% on 9 November 2026: Why Sun Pharma Advanced Research Shares Rose Despite Weak Sentiment on D-Street and What to Check

SPARC rose up to 11% on 9 Nov 2026 to Rs 219.49 vs a Rs 197.03 close (Mint). No company news found; Q2 loss narrowed, and a P/E near 4 reflects a one-off gain, not a measure of value.

The SPARC share price rose as much as 11% on 9 November 2026 even as the broader market stayed weak, and Sun Pharma Advanced Research shares touched an intraday high of Rs 219.49. Mint asks what is boosting the medical stock. This article sets out the price data, the possible reasons, the latest quarterly numbers, the drug pipeline, valuation and risks. I did not find a company filing for 9 November, so I separate what is reported from what is guesswork.

Click Here – Get Free Investment Predictions

SPARC Share Price on 9 November: Open, High and Snapshots

SPARC share price: item	Reading	Source and time
SPARC share price close in the Sunday Muhurat session	Rs 197.03, up 1.81%	Mint; Tickertape
SPARC share price open on 9 November	Rs 198.50	Mint
SPARC share price intraday high on 9 November	Rs 219.49	Mint
Rise from the previous close to the intraday high	About 11.4%	My arithmetic: 219.49 divided by 197.03
Mint stock widget for Sun Pharma Advanced Research shares as captured	Rs 210.40, up 6.80%	Mint
Univest stock page snapshot of the SPARC share price	Rs 210.66, up Rs 13.63 or 6.92%; day low Rs 196.50	Univest page, dated 9 November 2026
Mid-session SPARC share price reading	Rs 211, up 7.11%, at 12:53 PM	Screener
Earlier intraday high for Sun Pharma Advanced Research shares	Rs 215.10, up 8.43%	MarketsMOJO

The headline 11% for Sun Pharma Advanced Research shares is the intraday peak. The SPARC share price was up roughly 7% at several later readings, so these figures differ because they were taken at different times. Use a live quote on the Sun Pharma Advanced Research Company page for the current move. MarketsMOJO noted the Sensex was down 0.24% on the day, which fits Mint’s weak-sentiment description.

Why Sun Pharma Advanced Research Shares Surged: What Is Known

Possible reason Sun Pharma Advanced Research shares rose	Evidence found	Status
Pharma sector strength behind Sun Pharma Advanced Research shares	Nifty Pharma hit a fresh 52-week high of about 28,823 on 9 November, up 1.39%, as September-quarter results came in	Reported by Zee Business; a sector factor
Momentum in Sun Pharma Advanced Research shares	The stock rose 9.38% from Rs 176.90 to Rs 193.50 between 2 and 6 November and then closed at Rs 197.03	MarketsMOJO; Tickertape
Technical breakout in Sun Pharma Advanced Research shares	MarketsMOJO says the price cleared its 50-day moving average on 9 November	A third-party reading
Quarterly results	Q2 FY27 loss narrowed from a year ago on much higher revenue	Reported 3 November; mixed views
Company news on Sun Pharma Advanced Research shares	No announcement found for 9 November	Not confirmed

No source I found links the jump to a single event. The week before it had already brought a gain of nearly 12%, per Trendlyne, so Monday’s rise extended a trend. A stock with a small free float and a story of clinical milestones can move sharply when sector money flows in. That is my reading, not a reported cause.

Screen pharma stocks on the Univest Screener

SPARC Q2 FY27 Results and the Pipeline Behind Sun Pharma Advanced Research Shares

SPARC Q2 FY27 item	Reading	Source and note
Revenue, September 2026 quarter	About Rs 54 crore, up 581.7% year on year	Trendlyne
Net loss, September 2026 quarter	About Rs 25 crore, a 67.6% improvement year on year	Trendlyne
June 2026 quarter	Net sales of Rs 40 crore and a net loss of Rs 21 crore	MarketsMOJO
Quarter on quarter	Revenue up about 35% and loss about 19% wider	My arithmetic on the two quarters above
A different reading of the quarter	MarketsMOJO describes flat performance and cites net sales of Rs 30.03 crore	Conflicts with Trendlyne; I could not reconcile it
March 2026 quarter	A large one-off gain produced a profit turnaround	Univest’s earlier article

Read the exchange filing for the exact Q2 numbers, because the two data sources disagree. SPARC is a research-stage company, so revenue is lumpy and depends on licensing and milestone income. Its pipeline includes Sezaby for neonatal seizures, SPARC-121 for alopecia areata, SPARC-122 for multiple cancers and vodobatinib for Parkinson’s disease. A management update in January 2026 also pointed to GL0034 for type 2 diabetes in Phase 2. Clinical results can swing Sun Pharma Advanced Research shares either way, and the SPARC share price reflects that.

Download the Univest iOS App or Univest Android App to get results alerts and track pharma stocks.

SPARC Share Price Valuation: Why the P/E Misleads

Check on the SPARC share price	Reading	Source and date
Market capitalisation of Sun Pharma Advanced Research shares	About Rs 6,847 crore at Rs 211	Screener, 9 November
Book value per share	About Rs 44.3, so price is about 4.8 times book	Screener; my arithmetic
Trailing P/E	About 4.2 on Screener and 3.91 on the Univest page	Distorted by the one-off gain; not a guide to value
52-week range	Rs 108 to Rs 289	Tickertape; MarketsMOJO
Rs 219.49 high against the 52-week high	About 24% below Rs 289	My arithmetic
Rs 219.49 high against the 52-week low	About 2.0 times Rs 108	My arithmetic
Promoter holding in Sun Pharma Advanced Research shares	About 65.7%	Screener

A P/E near 4 looks low only because trailing profit includes a large one-off gain, while the underlying R&D business still loses money. A Google Finance table for the September 2025 quarter showed negative total equity, so check the latest balance sheet before relying on the book value. SPARC was demerged from Sun Pharmaceutical Industries but is not a subsidiary of it. See our earlier SPARC buy, hold or sell guide for the earlier price context.

SPARC Share Price Checklist and Risks

Investor situation	Questions to consider
Existing holder	Is my cost near the Rs 197 to Rs 219 range, and can I sit through a reversal after an 11% intraday jump?
New buyer	Do I understand a clinical-stage business with losses, one-off gains and no dividend?
Short-term trader	The stock rose about 12% in a week; where would I accept being wrong?
Long-term investor	How do I weigh trial outcomes, funding needs and a 65.7% promoter holding?

Trial results are binary events, so Sun Pharma Advanced Research shares can fall as fast as it rose. The sector tailwind from Nifty Pharma may fade, and a quiet day for the stock after a jump is common. Judge the business through filings and trial updates, not a single session.

Conclusion

The SPARC share price jumped as much as 11% on 9 November 2026 as Sun Pharma Advanced Research shares outran a weak market, helped by a strong pharma sector and a week of momentum. No company announcement was found, the Q2 figures differ across sources and a P/E near 4 reflects a one-off gain. Check a live quote and the filings, and consult a SEBI-registered adviser before acting.

Frequently Asked Questions on the SPARC Share Price

Why did the SPARC share price surge on 9 November?

Ans. Mint reported a rise of about 11% at the intraday high of Rs 219.49 despite weak sentiment. I found no company announcement. Possible factors are a record high in Nifty Pharma, a week of momentum and a narrower Q2 loss, but none is confirmed as the cause.

How much did Sun Pharma Advanced Research shares rise?

Ans. The intraday high of Rs 219.49 was about 11.4% above the Rs 197.03 close, by my arithmetic. Later readings showed gains near 7%, including Rs 210.66 on the Univest page. The figures differ by time, so check a live quote.

What were the SPARC Q2 FY27 results?

Ans. Trendlyne shows revenue of about Rs 54 crore and a net loss of about Rs 25 crore, an improvement of 67.6% from a year earlier. MarketsMOJO cites different sales figures, so read the exchange filing before relying on either set.

Is SPARC a subsidiary of Sun Pharma?

Ans. No. SPARC was created through a demerger of Sun Pharmaceutical Industries' innovative R&D business, but it is a separate listed company, and its founders hold about 65.7%, per Screener. Its fortunes depend on its own pipeline and licensing deals.

Is the SPARC share price expensive after the surge?

Ans. For Sun Pharma Advanced Research shares, a P/E near 4 is misleading because trailing profit includes a large one-off gain in the March 2026 quarter, while the research business still reports losses. The price is about 4.8 times book value at Rs 211, per Screener. Check the balance sheet before judging value.

What is the 52-week range of the SPARC share price?

Ans. Tickertape and MarketsMOJO show a range of Rs 108 to Rs 289. The 9 November high of Rs 219.49 sits about 24% below the top of the range, by my arithmetic. The range shows how volatile the stock has been.

Can the SPARC share price keep rising?

Ans. Nobody can say whether Sun Pharma Advanced Research shares will keep rising. Momentum and a strong sector can help, but trial results, losses and profit-taking can reverse a rise. The stock gained nearly 12% in the week before 9 November, so some of the move may already be in the price.

What should investors do about the SPARC share price?

Ans. Univest does not recommend any security. A holder can check cost and position size, a new buyer can read the filings and pipeline updates, and a trader can set exit rules. A SEBI-registered adviser can give personal advice.